within Pharmacolibrary.Drugs.ATC.A;

model A04AA03_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00055,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.164,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.048,
    k12             = 34,
    k21             = 34
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A04AA03_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tropisetron is a selective 5-HT3 receptor antagonist used primarily to prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery. It is approved for use in several countries but is less widely used today compared to other antiemetics such as ondansetron.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Kees, F, et al., &amp; Grobecker, H (2001). Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. <i>British journal of clinical pharmacology</i> 52(6) 705–707. DOI:<a href=&quot;https://doi.org/10.1046/j.0306-5251.2001.01512.x&quot;>10.1046/j.0306-5251.2001.01512.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11736884/&quot;>https://pubmed.ncbi.nlm.nih.gov/11736884</a></p></li><li><p>Gaedicke, G, et al., &amp; Kutz, K (1996). Pharmacokinetics of the 5HT3 receptor antagonist tropisetron in children. <i>Pediatric hematology and oncology</i> 13(5) 405–416. DOI:<a href=&quot;https://doi.org/10.3109/08880019609030852&quot;>10.3109/08880019609030852</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10897812/&quot;>https://pubmed.ncbi.nlm.nih.gov/10897812</a></p></li><li><p>Pickering, G, et al., &amp; Dubray, C (2008). Acetaminophen reinforces descending inhibitory pain pathways. <i>Clinical pharmacology and therapeutics</i> 84(1) 47–51. DOI:<a href=&quot;https://doi.org/10.1038/sj.clpt.6100403&quot;>10.1038/sj.clpt.6100403</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17957182/&quot;>https://pubmed.ncbi.nlm.nih.gov/17957182</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A04AA03_1;
